Volume 27, Number 6—June 2021
Research
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA
Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy Leber
Table 4
Risk factors for longer duration of hospitalization in children hospitalized with Mycoplasma pneumoniae infection, Ohio, USA, 2015–2019*
| Risk factor | Univariate analysis |
Multivariable analysis |
|||
|---|---|---|---|---|---|
| RR (95% CI) | p value | aRR (95% CI) | p value | ||
| Female sex | 0.85 (0.63–1.15) | 0.2852 | |||
| Age, y | 0.98 (0.95–1.01) | 0.2213 | |||
| Underlying condition | 1.25 (0.92–1.71) | 0.1592 | |||
| Any previous visit | 0.83 (0.58–1.16) | 0.2734 | |||
| Macrolide resistance | 2.91 (1.56–5.44) | 0.0008 | 2.04 (0.97–4.32) | 0.061 | |
| Abnormal respiratory examination | 1.14 (0.77–1.7) | 0.5103 | |||
| Previous treatment with antimicrobial drugs | 0.94 (0.69–1.27) | 0.6882 | |||
| Previous nonmacrolide antimicrobial drugs | 0.97 (0.71–1.31) | 0.8204 | |||
| Positive viral test | 0.96 (0.69–1.34) | 0.8122 | |||
| MRMp and positive viral test | 1.67 (0.51–5.44) | 0.3946 | |||
*Bold type indicates statistical significance. aRR, adjusted RR; MRMp, macrolide-resistant Mycoplasma pneumoniae; RR, relative risk.
1Current affiliation: Marshall University, Huntington, West Virginia, USA.
Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.